

Supplemental Table 1. Shifts from baseline to postbaseline values in lipid concentrations in Part B

	Sirukumab						All sirukumab
	Placebo	Placebo → Sirukumab 100 mg q2w	100 mg q2w	100 mg q4w	50 mg q4w	25 mg q4w	
Treated patients, n	30	26	30	30	30	31	147
Total cholesterol (mg/dL)							
Patients with normal value (≤200) at baseline, n	14	12	14	16	16	20	78
Patients with abnormal value (>200) at week 24	0	5 (42)	8 (57)	9 (56)	8 (50)	14 (70)	44 (56)
Patients with normal value (≤200) at week 24	0	7 (58)	4 (29)	5 (31)	5 (31)	5 (25)	26 (33)
Patients with unknown value at week 24	14 (100)	0	2 (14)	2 (13)	3 (19)	1 (5)	8 (10)
Patients with abnormal value (>200) at baseline, n	15	13	15	13	12	11	64
Patients with abnormal value (>200) at week 24	1 (7)	12 (92)	14 (93)	10 (77)	11 (92)	9 (82)	56 (88)
Patients with normal value (≤200) at week 24	0	0	0	2 (15)	1 (8)	2 (18)	5 (8)
Patients with unknown values at week 24	14 (93)	1 (8)	1 (7)	1 (8)	0	0	3 (5)
HDL cholesterol (mg/dL)							
Patients with normal value (≥40) at baseline, n	24	21	27	26	27	31	132
Patients with abnormal value (<40) at week 24	0	1 (5)	0	0	1 (4)	0	2 (2)
Patients with normal value (≥40) at week 24	1 (4)	19 (91)	24 (89)	24 (92)	23 (85)	30 (97)	120 (91)
Patients with unknown value at week 24	23 (96)	1 (5)	3 (11)	2 (8)	3 (11)	1 (3)	10 (8)
Patients with abnormal value (<40) at baseline, n	5	4	2	3	1	0	10
Patients with abnormal value (<40) at week 24	0	2 (50)	0	0	0	0	2 (20)
Patients with normal value (≥40) at week 24	0	2 (50)	2 (100)	2 (67)	1 (100)	0	7 (70)
Patients with unknown value at week 24	5 (100)	0	0	1 (33)	0	0	1 (10)
LDL cholesterol (mg/dL)							
Patients with normal value (≤130) at baseline, n	20	17	20	21	21	25	104

Patients with abnormal value (>130) at week 24	0	6 (35)	7 (35)	7 (33)	9 (43)	7 (28)	36 (35)
Patients with normal value (≤130) at week 24	0	11 (65)	11 (55)	11 (52)	9 (43)	17 (68)	59 (57)
Patients with unknown value at week 24	20 (100)	0	2 (10)	3 (14)	3 (14)	1 (4)	9 (9)
Patients with abnormal value (>130) at baseline, n	9	8	9	8	7	6	38
Patients with abnormal value (>130) at week 24	1 (11)	7 (88)	5 (56)	6 (75)	6 (86)	5 (83)	29 (76)
Patients with normal value (≤130) at week 24	0	0	3 (33)	2 (25)	1 (14)	1 (17)	7 (18)
Patients with unknown value at week 24	8 (89)	1 (13)	1 (11)	0	0	0	2 (5)
<hr/>							
Triglycerides (mg/dL)							
Patients with normal value (≤250) at baseline, n	28	25	28	29	28	30	140
Patients with abnormal value (>250) at week 24	0	0	0	0	0	1 (3)	1 (1)
Patients with normal value (≤250) at week 24	1 (4)	24 (96)	25 (89)	26 (90)	25 (89)	28 (93)	128 (91)
Patients with unknown value at week 24	27 (96)	1 (4)	3 (11)	3 (10)	3 (11)	1 (3)	11 (8)
Patients with abnormal value (>250) at baseline, n	1	0	1	0	0	1	2
Patients with abnormal value (>250) at week 24	0	0	0	0	0	1 (100)	1 (50)
Patients with normal value (≤250) at week 24	0	0	1 (100)	0	0	0	1 (50)
Patients with unknown value at week 24	1 (100)	0	0	0	0	0	0

Data are presented as n or n (%). HDL, high-density lipoprotein; LDL, low-density lipoprotein